BullFrog AI Holdings, a Gaithersburg, Maryland-based AI company, announced on October 6, 2026 that it has achieved key project milestones under its commercial program with a top-5 global pharmaceutical company. By applying its proprietary AI and machine learning platform to proprietary neuropsychiatric multi-omic datasets, BullFrog AI identified and prioritized novel therapeutic targets for major depressive disorder (MDD).
“We’ve achieved important milestones and provided essential deliverables in our first commercial project with a global pharmaceutical company, identifying multiple novel and high-quality targets,” said BullFrog AI Founder and Chief Executive Officer Vin Singh. “We view this project as crucial commercial scale validation of our technology and believe our successes to date demonstrate the ability of our advanced AI and machine learning technologies to create high value assets.”
Expanding Across Neuropsychiatric Disease
As a core part of its commercial strategy, BullFrog AI is applying its technology to discovering and developing novel drug targets for other neuropsychiatric diseases, including schizophrenia and bipolar disorder. The company says it sees a significant opportunity to scale its technology into other high-impact therapeutic areas through deep analysis of biomedical datasets.
About BullFrog AI
BullFrog AI harnesses artificial intelligence and machine learning to advance pharmaceutical R&D and drug target discovery, providing AI-accelerated outputs that are optimized and human-validated. BullFrog AI operates through three complementary capabilities, deployable independently or as a combined platform: bfPREP™ for biology-aware data harmonization, bfLEAP® for causal AI analytics and patient subgroup discovery, and bfARENAS™ for structured, auditable decision support. The common thread across all three: every output is traceable, every analytical decision is logged, and every recommendation is designed to be reviewed and validated by the scientific team before it drives a decision.
